Signals Analytics Featured in TechCrunch

Signals Analytics Featured in TechCrunch

CRO Kobi Gershoni and EVP of Sciences Alexandra Eberhard discuss how the microbiome will lead a revolution in the consumerization of personalized medicine and diet in today's TechCrunch network. Check it out!CRO Kobi Gershoni and EVP of Sciences Alexandra Eberhard discuss how the microbiome will lead a revolution in the consumerization of personalized medicine and diet in today's TechCrunch network. Check it out!

Signals Analytics Raises $10 Million in New Funding Round with Qumra Capital

Signals Analytics Raises $10 Million in New Funding Round with Qumra Capital

We have closed a new funding round led by Qumra Capital, an Israeli late-stage venture fund focused on investments in technology companies’ rapid growth, for $10 million. The new capital will be used to accelerate Signals' global expansion and recruitment efforts in the US, Europe, and Israel. Qumra Managing Partner Boaz Dinte will join Signals' Board of Directors.

Signals Analytics Named A 2016 Cool Vendor In R&D For Manufacturers By Gartner

Signals Analytics Named A 2016 Cool Vendor In R&D For Manufacturers By Gartner

We're very excited to be recognized as a 2016 Cool Vendor in R&D for Manufacturers by Gartner. For us, we believe it's the validation that decision-makers in R&D, Marketing, and Product Development crave new insights for their decision making process – and our goal is to provide those insights based on the data that's out there. We want to arm our users, who face heavy decisions every day, with the evidence – to make those decisions with more clarity and confidence, and support innovation, growth and success

Signals' interview with UCB in PharmaTimes April issue

Signals' interview with UCB in PharmaTimes April issue

The big data to intelligence project [led by Signals] told us that patients wanted a better taste... the next step was to implement the insights for all our new drugs. The impact of the project has been widespread," says Heresh Rezavandi, UCB's ecosystem strategic intelligence lead. See today's article in Pharma Times on how Signals is helping UCB and other companies find innovative approaches to go "Beyond the Pill."

Signals and Johnson & Johnson Present on Trends in Beauty at IMCAS

Signals and Johnson & Johnson Present on Trends in Beauty at IMCAS

At IMCAS, the world's largest cosmetics exhibition fair, Signals' Dr. Alexandra V. Eberhard will be co-presenting with Thierry Oddos of J&J on the shift from professional to home-use in beauty products and devices. Signals and J&J have partnered on over 80 engagements covering product and technology trends spanning the entire space of healthcare.

Sequoia Backs Signals Analytics, Leading $15 Million Series B Funding Round

Sequoia Backs Signals Analytics, Leading $15 Million Series B Funding Round

“Our goal was to harness the power of external big data to produce high-level business insights that are immediately actionable for business leaders," says Signals CEO Gil Sadeh. "With support from Sequoia, Signals will continue to work with the greatest minds in data and computer science to develop a wider analytic portfolio designed for the Board room.”

Signals Analytics Featured in Forbes As The 'App Store for Innovation'

Signals Analytics Featured in Forbes As The 'App Store for Innovation'

Termed the “app store for innovation” by Forbes contributor Gil Press, Signals was featured last week empowering data-driven product managers looking to make smarter, faster around developing and launching new products. Interviewing Signals' CEO Gil Sadeh, Press focused on how Signals' serves product managers, who have traditionally been very data-driven, with a new approach that allows them to make meaning out of the explosion of new data that is found on the open web.

TDWI BI Journal Shares 4 Big Data Truths by Kobi Gershoni

TDWI BI Journal Shares 4 Big Data Truths by Kobi Gershoni

Check out TDWI's Business Intelligence Journal article "4 Big Data Truths" by Signals' Co-founder and Chief Research Officer Kobi Gershoni. Read on to see how he explains four distinct pillars of a successful big data strategy for decision makers in new product development.

Pharmaceuticals Breakfast Workshop in New Jersey May 11, 2015

Pharmaceuticals Breakfast Workshop in New Jersey May 11, 2015

Experience a new workshop over a free breakfast for pharma professionals on how to actually use intelligence from big data to answer key business challenges you face every day. Join Signals’ Dr. Shlomi Madar, Mariel Ackerman M.Sc. and other leading pharma professionals as we share with you how intelligence from big data has the potential to revolutionize the market research and R&D process, and give you useful tools that you can bring back to your organization immediately.

Join us May 19th in Boston at Signals’ FEI Roundtable Panel Event!

Join us May 19th in Boston at Signals’ FEI Roundtable Panel Event!

Unwind after a long day at FEI with Signals’ CEO Gil Sadeh and leading big data and innovation experts Frank Moss and Thomas Thurston. Join us for drinks, snacks and a stimulating panel featuring some of the leading minds in making big data analytics meaningful for innovation and product teams.

Signals Speaking at ENG's 2015 Innovation Fusion Event

Signals Speaking at ENG's 2015 Innovation Fusion Event

Come see Signals' very own Executive Vice President of Life Sciences, Dr. Alexandra V. Eberhard speak April 21-22 in Berlin at ENG's Innovation Fusion 2015: NPD Technology Excellence for Chem & FMCG. Bringing together leading experts in R&D and innovation from both the specialty chemical as well as the fast-moving consumer goods sectors.

VentureBeat: 3 Ways Open Data is Revolutionizing NPD

VentureBeat: 3 Ways Open Data is Revolutionizing NPD

Signals' CEO Gil Sadeh graces the front page of VentureBeat today sharing three ways that open data on the web is revolutionizing the new product development process for companies. See how using open data reveals what people really need and don’t have on one end, and what technologies can make a meaningful impact on the other — here lies the sweet spot where the next breakthrough product is waiting.